EN

Company News

Company News

Home > News Center > Company News
CelluPro Leads Development of New Group Standard for Serum-Free Mammalian Cell Culture Medium

Jun.01, 2025

CelluPro Leads Development of New Group Standard for Serum-Free Mammalian Cell Culture Medium

The group standard for Serum-Free Mammalian Cell Culture Medium (Standard No.: T/CSBME 086-2025), drafted under the leadership of Yantai CelluPro Biological Technology Co., Ltd., was officially released.
CelluPro’s Culture Media Contributes to the Successful Approval of the New Drug Telitacicept, a Class 1 Innovative Biological Product

Mar.09, 2021

CelluPro’s Culture Media Contributes to the Successful Approval of the New Drug Telitacicept, a Class 1 Innovative Biological Product

On March 9, 2021, the National Medical Products Administration of China approved Telitacicept, a Class 1 innovative drug developed by RemeGen, for the treatment of systemic lupus erythematosus.
CelluPro Culture Media Supports China’s First Developed ADC New Drug Approval

Jun.09, 2021

CelluPro Culture Media Supports China’s First Developed ADC New Drug Approval

On June 9, 2021, China's National Medical Products Administration (NMPA) announced the approval of Disitamab Vedotin (Brand Name: Aidixi®, Research Code: RC48), the country’s first original antibody-drug conjugate (ADC) new drug.

Resources

Biotechnology Learning Center

OEM Questionnaire

Support

To gain more bio process information

We Value Your Privacy

We use cookies to improve your experience and analyze website performance. By continuing to browse or clicking “Accept”, you consent to our use of cookies.